Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Dansk

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Surfactant therapy of respiratory distress syndrome

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. DBCG Kvalitetsdatabase for Brystkræft – resumé af årsrapport 2020

    Publikation: Bidrag til tidsskriftTidsskriftartikelFormidling

  3. Nærdødsoplevelser

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hjertestop hos en patient med langt QT-syndrom i androgendeprivationsterapi

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Leder - Rosenrot

    Publikation: Bidrag til tidsskriftLederForskning

Vis graf over relationer

The use of immunosuppressive agents can be vital. However, immunosuppression may also cause reactivation of hepatitis B virus (HBV) infection which can be fatal. To reduce the risk of reactivation prophylactic antiviral treatment is recommended in patients with chronic HBV infection. In patients with former HBV infection prophylaxis is also recommended if anti-CD20 agents are used and in cases of transplantation. Immunosuppression in patients with hepatitis C virus (HCV) infection does not seem to lead to severe hepatic manifestations, and reactivation of HCV in this context generally has a mild clinical course.

Bidragets oversatte titelProphylaxis of reactivation of hepatitis B and hepatitis C virus infection in immunosuppressive therapy
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind181
Udgave nummer6
ISSN0041-5782
StatusUdgivet - 4 feb. 2019

    Forskningsområder

  • Antiviral Agents, Hepacivirus, Hepatitis B/immunology, Hepatitis B virus, Hepatitis C/immunology, Humans, Immunosuppressive Agents/adverse effects, Virus Activation

ID: 59181240